Time for a new approach to drug development for rare systemic autoinflammatory diseases

E.D. and R.G.M. are co-founders of TARN, N.M.Z. is a coordinator of TARN, and M.R. is a member of its steering committee. The authors would like to acknowledge other core steering committee members of TARN: S. Canna, F. Dedeoglu and K. Durrant. We also extend our gratitude to F. Garcia-Bournissen for invaluable contributions to the conceptualization of this Comment, which were pivotal in refining the arguments and perspectives explored.

Comments (0)

No login
gif